We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lipoprotein(a) Concentrations Correlate With LDL-C in Diabetic Children

By LabMedica International staff writers
Posted on 30 Nov 2021
Cardiovascular disease (CVD) is a significant cause of mortality in those with diabetes. More...
Increased apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) have been shown in pediatric patients with diabetes with worsening glycemic control.

Lipoprotein(a) (Lp(a)) is a highly atherogenic lipoprotein that attaches to the apoB 100 moiety of LDL-C particles. Lp(a) is concentration is generally fully expressed by the second year in childhood. Lp(a) is highly heritable, with great concordance between parental levels.

Pediatric Endocrinologists at the University of Alabama School of Medicine (Birmingham, AL, USA) investigate the relationships between serum concentrations of Lp(a) with low-density lipoprotein cholesterol (LDL-C), race, body mass index (BMI), and HbA1c in children with diabetes. Their secondary aim was to evaluate the factors associated with elevated Lp(a) levels. The carried out across-sectional retrospective chart review of pediatric patients, ages 12-19 years, including 607 type 1 diabetes (T1D) and 93 type 2 diabetes (T2D); 49% were male, mean age was 13.2 ± 3.08 years, and the median Lp(a) was 8.00 mg/dL. In addition to standard lipid profile testing, the clinical laboratory also offered Vertical Auto Profile (VAP) testing through a commercial laboratory (Atherotech, Birmingham, AL, USA).

The investigators reported that the Black children had an increased relative risk (RR) of higher Lp(a) compared with White ones (RR 1.25). The median Lp(a) was significantly higher in Black people than in White people, 9 (6-14) versus 7 (5-11). Among patients with T1D, Black people had an increased relative risk of higher Lp(a) than White people (RR 1.23). In T2D, Black participants have 43% higher risk of having elevated Lp(a) than White participants (RR 1.43). In T1D, a 5 mg/dL increase in LDL-C results in 2% increase in Lp(a). In T2D, a 5 mg/dL increase of LDL-C results in an increase of Lp(a) by 3%. LDL-C and BMI are independently associated with Lp(a) (RR = 1.02 and RR = 0.98), respectively. Interestingly, patients with T1D had higher mean levels of Lp(a) despite having a lower BMI compared to children with T2D. Patients with T1D had higher mean HbA1c than those with T2D (9.14% [5.88-12.4] versus 8.27% [5.67-10.87]).

The authors concluded that Lp(a) is strongly associated with LDL-C in children with diabetes, indicating a reduction of LDL-C may additionally reduce cardiovascular risk by lowering Lp(a) levels. Black children with diabetes have a significant burden of Lp(a) concentrations compared with White children. It may be important to consider Lp(a) screening in children with diabetes for disease risk management and implement stricter therapeutic goals for LDL-C reduction. The study was published in the November, 2021 issue of Journal of the Endocrine Society.

Related Links:
University of Alabama School of Medicine
Atherotech



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method combines metagenomic sequencing with computational filtering to identify likely disease-causing bacteria and viruses (Image Credit: iStock)

Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis

Infections of the central nervous system, such as meningitis and encephalitis, can be severe and require prompt diagnosis and treatment. Clinicians typically evaluate cerebrospinal fluid alongside symptoms... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.